1. Artificial Neural Network Model for Predicting Lung Cancer Survival
   Hansapani Rodrigo et al, 2017, JDAIP CrossRef
2. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
   Suresh S. Ramalingam et al, 2017, Clinical Lung Cancer CrossRef
3. Endobronchial Ultrasound (EBUS) for Staging Lung Cancer in the Elderly Population—Specific Procedural and Medication Issues
   Lindsey Taylor et al, 2018, Curr Geri Rep CrossRef
4. Increasing age predicts poor cervical cancer prognosis with subsequent effect on treatment and overall survival
   Bridget A. Quinn et al, 2018, Brachytherapy CrossRef
5. ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
   Hongbo Zhao et al, 2018, Front. Pharmacol. CrossRef
6. KIAA1199 promotes invasion and migration in non-small-cell lung cancer (NSCLC) via PI3K-Akt mediated EMT
   Zhiyuan Tang et al, 2018, J Mol Med CrossRef
7. Lung cancer detected on coronary artery calcium scoring computed tomography: factors delaying diagnosis and predictors of survival
   Jin Young Kim et al, 2018, Acta Radiol CrossRef
8. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy.
   Nikhil Sebastian et al, 2019, Radiother Oncol CrossRef
9. Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel
   C J Langer et al, 2015, Br J Cancer CrossRef
10. Prognostic value of a novel scoring system using inflammatory response biomarkers in non‐small cell lung cancer: A retrospective study
    Yan Wang et al, 2019, Thorac Cancer CrossRef
11. “Age matters”—German claims data indicate disparities in lung cancer care between elderly and young patients
    Julia Walter et al, 2019, PLoS ONE CrossRef
12. Early treatment with metformin induces resistance against tumor growth in adult rats
    Amanda B Trombini et al, 2015, Cancer Biology & Therapy CrossRef
13. Prognostic Value of Tumor-to-Blood Standardized Uptake Ratio in Patients with Resectable Non-Small-Cell Lung Cancer
    Seunghyeon Shin et al, 2017, Nucl Med Mol Imaging CrossRef
14. Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients
    Yu Yu et al, 2017 CrossRef
15. Hepatocellular carcinoma in elderly: Clinical characteristics, treatments and outcomes compared with younger adults
    Hui Guo et al, 2017, PLoS ONE CrossRef
16. Distinct Prognostic Factors in Patients with Stage I Non–Small Cell Lung Cancer with Radiologic Part-Solid or Solid Lesions
    Fangqiu Fu et al, 2019, Journal of Thoracic Oncology CrossRef
17. Prognostic Factors Associated with Lung Cancer Survival: A Population-Based Study in Southern Spain
    Isabel Linares et al, 2019, COR CrossRef
18. Association of Time-Varying Rest-Activity Rhythm With Survival in Older Adults With Lung Cancer
    Lou-Ching Kuo et al, 2020, Cancer Nursing CrossRef
19. Comparing the effectiveness of different EGFR‐TKIs in patients with EGFR mutant non–small‐cell lung cancer: A retrospective cohort study in Taiwan
    Yao‐Yu Hsieh et al, 2020, Int. J. Cancer CrossRef
20. Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer
    Qing Huang et al, 2020, Medicine CrossRef
21. Outcomes of Surgically Treated Patients with Stage IIB Non-small Cell Lung Cancer, a Single Center Experience
    Muhammet Sayan et al, 2020, Indian J Surg CrossRef
22. Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade.
    Miriam Möller et al, 2020, J Immunother CrossRef
23. Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial
    Jonas Kuon et al, 2020, Trials CrossRef
24. Downregulation of KIAA1199 by miR‐486‐5p suppresses tumorigenesis in lung cancer
    Anqi Wang et al, 2020, Cancer Med CrossRef
25. Prognoses, outcomes, and clinicopathological characteristics of very elderly patients with hepatocellular carcinoma who underwent hepatectomy
    Shingo Shimada et al, 2020, World J Surg Onc CrossRef
26. Surgery in patients with small cell lung cancer: A period propensity score matching analysis of the Seer database, 2010‑2015
    Xiaojun Du et al, 2019, Oncol Lett CrossRef
27. Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR)
    Kyoichi Okishio et al, 2020, ESMO Open CrossRef
28. The impact of beta blockers on survival outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors
    Michael S. Oh et al, 2020, Clinical Lung Cancer CrossRef
29. circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway
    Yutang Huang et al, 2020, Molecular Therapy - Nucleic Acids CrossRef
30. Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database.
    Begoña Campos-Balea et al, 2020, Thorac Cancer CrossRef
31. Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer
    Jeong-Oh Kim et al, 2020, Cancers CrossRef
32. Validation of the 8th lung cancer TNM classification and clinical staging system in a German cohort of surgically resected patients
    Samantha Taber et al, 2020 CrossRef
33. Acid-suppressive agents and survival outcomes in patients with cancer: a systematic review and meta-analysis
    Hyun Jin Song et al, 2020, Int J Clin Oncol CrossRef
34. Health Disparities in Environmental and Occupational Lung Disease
    Emily Brigham et al, 2020, Clinics in Chest Medicine CrossRef
35. Exceptional Survival Among Kentucky Stage IV Non‐small Cell Lung Cancer Patients: Appalachian Versus Non‐Appalachian Populations
    Vira Pravosud et al, 2020, The Journal of Rural Health CrossRef
36. Identification of Prognostic Genes and Pathways in Lung Adenocarcinoma Using a Bayesian Approach
    Yu Jiang et al, 2017, Cancer Inform CrossRef
37. Comprehensive Perspective for Lung Cancer Characterisation Based on AI Solutions Using CT Images
    Tania Pereira et al, 2020, JCM CrossRef
38. Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study
    Hee Sang Hwang et al, 2021, Cancer Res Treat CrossRef
39. Lung Cancer Attributed Mortality Among 316,336 Early Stage Breast Cancer Cases Treated by Radiotherapy and/or Chemotherapy, 2000–2015: Evidence From the SEER Database
    Semaw Ferede Abera et al, 2021, Front. Oncol. CrossRef
40. A seven-gene prognostic signature predicts overall survival of patients with lung adenocarcinoma (LUAD)
    Aisha Al-Dherasi et al, 2021, Cancer Cell Int CrossRef
41. Factors associated with early lung cancer mortality: a systematic review
    Christos Chouaïd et al, 2021, Expert Review of Anticancer Therapy CrossRef
42. Is time-to-treatment associated with higher mortality in Korean elderly lung cancer patients?
    Kyu-Tae Han et al, 2021, Health Policy CrossRef
43. Allele frequency deviation (AFD) as a new prognostic model to predict overall survival in lung adenocarcinoma (LUAD)
    Aisha Al-Dherasi et al, 2021, Cancer Cell Int CrossRef
44. Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer
    Prantesh Jain et al, 2021, Front. Oncol. CrossRef
45. Longitudinal patient-reported outcomes and survival among early-stage non-small cell lung cancer patients receiving stereotactic body radiotherapy
    Kea Turner et al, 2021, Radiotherapy and Oncology CrossRef
46. Racial Differences in Survival Among Advanced-stage Non–small-Cell Lung Cancer Patients Who Received Immunotherapy: An Analysis of the US National Cancer Database (NCDB)
    Anjali Gupta et al, 2022 CrossRef
47. THE EFFECTS OF TUMOR LOCALIZATION ON SMALL CELL LUNG CANCER AND ITS ASSOCIATION WITH PROGNOSIS
    Sertan BULUT et al, 2021 CrossRef
48. Prognostic factors for treatment response and survival outcomes after first-line management of Stage 4 non-small cell lung cancer: A real-world Indian perspective
    Avneet Garg et al, 2022, Lung India CrossRef
49. Prognostic Values of Inflammatory Indexes and Clinical Factors in Patients with Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma and Treated with Tyrosine Kinase Inhibitors
    Bee-Song Chang et al, 2022, JPM CrossRef
50. Association of Personal Characteristics and Effectiveness of Immunotherapy in Late-Stage Non-Small Cell Lung Cancer: A Systematic Review
    Krishna Patel et al, 2022 CrossRef
51. A nine-gene signature identification and prognostic risk prediction for patients with lung adenocarcinoma using novel machine learning approach
    Eskezeia Yihunie Dessie et al, 2022, Computers in Biology and Medicine CrossRef
52. Prognostic Impact of EGFR Amplification and Visceral Pleural Invasion in Early Stage Pulmonary Squamous Cell Carcinomas Patients after Surgical Resection of Primary Tumor
    Luís Miguel Chinchilla-Tábora et al, 2022, Cancers CrossRef
53. Association of Diabetes Severity and Mortality with Lung Squamous Cell Carcinoma
    Chih-Hsiung Su et al, 2022, Cancers CrossRef
54. The nomogram for the prediction of overall survival in patients with metastatic lung adenocarcinoma undergoing primary site surgery: A retrospective population-based study
    Chao Ma et al, 2022, Front. Oncol. CrossRef
55. Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer
    Marko Bitenc et al, 2022 CrossRef
56. DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome
    Kayla Guidry et al, 2022 CrossRef
57. Adaptation criterion for segmentectomy in small‐sized early stage non‐small cell lung cancer
    Nozomu Motono et al, 2022, Thoracic Cancer CrossRef
58. Invasive area to tumor ratio is a significant prognostic factor for non‐small cell lung cancer
    Nozomu Motono et al, 2022, Thoracic Cancer CrossRef
59. Real-World Patterns and Decision Drivers of Radiotherapy for Lung Cancer Patients in Romania: RADIO-NET Study Results
    Mihai-Teodor Georgescu et al, 2022, Diagnostics CrossRef
60. The Effect of Body Mass Index on Survival in Lung Cancer
    Fatma Yağmur Evcil et al, 2022, Nutrition and Cancer CrossRef
61. Development of Clinical Prediction Score for Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients
    Chawalit Chayangsu et al, 2023, Healthcare CrossRef
62. Lung Cancer and Lung Transplantation
    Renea Jablonski, 2023, Curr Pulmonol Rep CrossRef
63. Favorable Mortality-to-Incidence Ratio Trends of Lung Cancer in Countries with High Computed Tomography Density
    Yao-Tung Wang et al, 2023, Medicina CrossRef
64. Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer
    Yinghao Zhao et al, 2023, Front. Oncol. CrossRef
65. Burden of tracheal, bronchus, and lung cancer in North Africa and Middle East countries, 1990 to 2019: Results from the GBD study 2019
    Shaghayegh Khanmohammadi et al, 2023, Front. Oncol. CrossRef
66. Cardiovascular, respiratory and all-cause (natural) health endpoint estimation using a spatial approach in Malaysia
    Mohamad Iqbal Mazeli et al, 2023, Science of The Total Environment CrossRef
67. Expression of RBM3 in Non-Small Cell Lung Cancer and Its Correlation with Prognosis of Patients
    东帅 黄, 2023, ACM CrossRef
68. Occupational asbestos exposure and survival among lung cancer patients
    Hugo Noelle et al, 2023, Lung Cancer CrossRef
69. Clinical characteristics, management, and outcomes of patients with primary cardiac angiosarcoma: A systematic review
    Diego Chambergo-Michilot et al, 2023, J Cardiovasc Thorac Res CrossRef
70. null
    Bianca Princeton et al, 2023 CrossRef
71. Effect of high-level PM2.5 on survival in lung cancer: a multicenter cohort study from Hebei Province, China
    Yanyu Liu et al, 2023, Environ Sci Pollut Res CrossRef
72. Metastatic non-small-cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021–2026
    Xinmei Zhu et al, 2023, Future Oncology CrossRef
73. Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial
    Yunpeng Yang et al, 2023, Sig Transduct Target Ther CrossRef
74. Prognostic factors and predictive nomogram models for early death in elderly patients with hepatocellular carcinoma: a population-based study
    Hao Zhou et al, 2023, Front. Mol. Biosci. CrossRef
75. Cell-Free DNA 5-Hydroxymethylcytosine Signatures for Lung Cancer Prognosis
    Jianming Shao et al, 2024, Cells CrossRef
76. Age at lung cancer diagnosis in females versus males who never smoke by race and ethnicity
    Batel Blechter et al, 2024, Br J Cancer CrossRef
77. Factors associated with survival of patients with advanced lung cancer and long travel distances
    Hui-Fen Chan et al, 2023, Journal of the Formosan Medical Association CrossRef
78. Lung cancer outcomes in the elderly: potential disparity in screening
    Anupama Singh et al, 2024 CrossRef
79. Distinguishing optimal candidates for primary tumor resection in patients with metastatic lung adenocarcinoma: A predictive model based on propensity score matching
    Yuying Qi et al, 2024, Heliyon CrossRef
80. null
    Dhruv Trivedi et al, 2023 CrossRef
81. null
    Gokcen Ömeroğlu Şimşek et al, 2023 CrossRef
82. ImmunoChemoradiation for Non-Small Cell Lung Cancer: A Meta-Analysis of Factors Influencing Survival Benefit in Combination Trials
    Huei-Tyng Huang et al, 2024, International Journal of Radiation Oncology*Biology*Physics CrossRef
83. Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis
    Yi Liu et al, 2024, BMC Pulm Med CrossRef
84. Sex Difference in Disease-Related Adverse Events Post-Diagnosis of Lung Cancer Brain Metastases in Medicare Individuals ≥ 66 Years of Age
    Mantas Dmukauskas et al, 2024, Cancers CrossRef
85. Nomogram predicting overall and cancer specific prognosis for poorly differentiated lung adenocarcinoma after resection based on SEER cohort analysis
    Weijian Song et al, 2024, Sci Rep CrossRef
86. Patient‐ and Areal‐Level Risk Factors Associated With Lung Cancer Mortality in Victoria, Australia: A Bayesian Spatial Survival Analysis
    Getayeneh Antehunegn Tesema et al, 2024, Cancer Medicine CrossRef
87. Spine Stereotactic Body Radiation Therapy in Geriatric Patients: Implications of Age and Dose on Iatrogenic Vertebral Compression Fracture Risk
    Adrian Wai Chan et al, 2024, International Journal of Radiation Oncology*Biology*Physics CrossRef
88. Burdens of Tracheal, Bronchus, and Lung Cancer From 1990 to 2021 in China Compared to the Global Projection of 2036: Findings From the 2021 Global Burden of Disease Study
    Yuxing Chen et al, 2025, Thoracic Cancer CrossRef